Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The United Laboratories International Holdings ( (HK:3933) ) has shared an announcement.
The United Laboratories International Holdings has scheduled a board meeting for 24 March 2026 to review and approve its annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could signal management’s confidence in the company’s financial performance and influence shareholder returns in the coming year.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands. It operates through various subsidiaries and focuses on manufacturing and selling pharmaceutical products, serving healthcare markets where demand for quality medicines supports recurring revenue streams and dividend distributions.
YTD Price Performance: 13.89%
Average Trading Volume: 9,751,330
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$26.04B
For an in-depth examination of 3933 stock, go to TipRanks’ Overview page.